Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical ReadinessUnusual Whales·Mar 30, 2026 at 01:13 PMFBT-0.05%IBBQ-0.39%
KDventures' portfolio company SVF Vaccines names Raheleh Nassaji as CEO to drive SVF-001 vaccine to phase 1 trials.Unusual Whales·Feb 10, 2026 at 01:02 PMIBBQ-0.39%SBIO-0.49%
